CA2287204A1 - Methods of production of an amidated peptide through the use of a fusion protein - Google Patents
Methods of production of an amidated peptide through the use of a fusion protein Download PDFInfo
- Publication number
- CA2287204A1 CA2287204A1 CA002287204A CA2287204A CA2287204A1 CA 2287204 A1 CA2287204 A1 CA 2287204A1 CA 002287204 A CA002287204 A CA 002287204A CA 2287204 A CA2287204 A CA 2287204A CA 2287204 A1 CA2287204 A1 CA 2287204A1
- Authority
- CA
- Canada
- Prior art keywords
- fusion protein
- peptide
- expressed
- sequence
- transgenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 108020001507 fusion proteins Proteins 0.000 title claims description 49
- 102000037865 fusion proteins Human genes 0.000 title claims description 45
- 238000007112 amidation reaction Methods 0.000 claims abstract description 11
- 230000009435 amidation Effects 0.000 claims abstract description 10
- 230000017730 intein-mediated protein splicing Effects 0.000 claims description 26
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 229920002101 Chitin Polymers 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 102400000921 Gastrin Human genes 0.000 claims description 6
- 108010052343 Gastrins Proteins 0.000 claims description 6
- 239000005864 Sulphur Substances 0.000 claims description 6
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- -1 ammonium ions Chemical class 0.000 claims description 5
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 229940045644 human calcitonin Drugs 0.000 claims description 5
- 239000003488 releasing hormone Substances 0.000 claims description 5
- 108010068072 salmon calcitonin Proteins 0.000 claims description 5
- 230000003248 secreting effect Effects 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 108060003100 Magainin Proteins 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- WCSPDMCSKYUFBX-ZJZGAYNASA-N (2s)-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanamide Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 WCSPDMCSKYUFBX-ZJZGAYNASA-N 0.000 claims description 2
- QVOBNSFUVPLVPE-ROUUACIJSA-N 2-[[(2s)-2-[[2-[[(2s)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 QVOBNSFUVPLVPE-ROUUACIJSA-N 0.000 claims description 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 claims description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims description 2
- 108010010737 Ceruletide Proteins 0.000 claims description 2
- 101800001982 Cholecystokinin Proteins 0.000 claims description 2
- 102100025841 Cholecystokinin Human genes 0.000 claims description 2
- 101800000414 Corticotropin Proteins 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 101800000164 FMRF-amide Proteins 0.000 claims description 2
- IGOYNRWLWHWAQO-JTQLQIEISA-N Gly-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-JTQLQIEISA-N 0.000 claims description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 2
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 claims description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 2
- 101710151321 Melanostatin Proteins 0.000 claims description 2
- 102400000064 Neuropeptide Y Human genes 0.000 claims description 2
- 102400000050 Oxytocin Human genes 0.000 claims description 2
- 101800000989 Oxytocin Proteins 0.000 claims description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 2
- 241000815416 Parasa pastoralis Species 0.000 claims description 2
- ZKSLXIGKRJMALF-MGHWNKPDSA-N Phe-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)N ZKSLXIGKRJMALF-MGHWNKPDSA-N 0.000 claims description 2
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- 101710142969 Somatoliberin Proteins 0.000 claims description 2
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 2
- 108010078233 Thymalfasin Proteins 0.000 claims description 2
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
- 108010004977 Vasopressins Proteins 0.000 claims description 2
- 102000002852 Vasopressins Human genes 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 2
- 108010055460 bivalirudin Proteins 0.000 claims description 2
- 229960001500 bivalirudin Drugs 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 229930190815 caerulein Natural products 0.000 claims description 2
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 claims description 2
- 229960001706 ceruletide Drugs 0.000 claims description 2
- 229940107137 cholecystokinin Drugs 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
- 229960000258 corticotropin Drugs 0.000 claims description 2
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 2
- 229960001723 oxytocin Drugs 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 claims description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 2
- 229960004231 thymalfasin Drugs 0.000 claims description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 229960003726 vasopressin Drugs 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 239000007801 affinity label Substances 0.000 claims 2
- 108010036164 Glutathione synthase Proteins 0.000 claims 1
- 102100034294 Glutathione synthetase Human genes 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 101150082898 vma1 gene Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 13
- 238000011191 terminal modification Methods 0.000 abstract description 2
- 238000003776 cleavage reaction Methods 0.000 description 32
- 230000007017 scission Effects 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 150000007970 thio esters Chemical class 0.000 description 13
- 230000004927 fusion Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 102000055006 Calcitonin Human genes 0.000 description 7
- 108060001064 Calcitonin Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 229960004015 calcitonin Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 241000894007 species Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000006109 methionine Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000007026 protein scission Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000006228 peptide amidation Effects 0.000 description 2
- 238000010635 peptide amidation reaction Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003774 sulfhydryl reagent Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06B—TREATING TEXTILE MATERIALS USING LIQUIDS, GASES OR VAPOURS
- D06B1/00—Applying liquids, gases or vapours onto textile materials to effect treatment, e.g. washing, dyeing, bleaching, sizing or impregnating
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06C—FINISHING, DRESSING, TENTERING OR STRETCHING TEXTILE FABRICS
- D06C2700/00—Finishing or decoration of textile materials, except for bleaching, dyeing, printing, mercerising, washing or fulling
- D06C2700/13—Steaming or decatising of fabrics or yarns
- D06C2700/135—Moistening of fabrics or yarns as a complementary treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Textile Engineering (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Methods for the production of peptides, especially but not exclusively with carboxy-terminal modifications such as amidation, by recombinant means are provided.
Description
METHODS OF PRODUCTION OF AN AMIDATED PEPTIDE THROUGH THE USE OF A FUSION
PROTEIN
The present invention is directed to the production of peptides, especially but not exclusively with carboxy-terminal modifications such as amidation, by recombinant means.
"Peptide" is a term loosely applied to a chain of amino acids, arbitrarily applied to sequences of three to over one hundred components, but possibly more, joined via their amino- and carboxy termini. There are many examples of naturally occurring peptides which function as hormones, messengers, growth factors, antimicrobials, o surfactants etc and a wide variety of medicinal and other applications can be envisaged.
Currently, there are at least three major sources of peptides, extraction from natural sources, chemical synthesis and from organisms transformed with recombinant DNA constructs. The advantage of the route using transformed organisms is the biological fidelity of the synthetic process, the ability to synthesise chemically unfavourable sequences, the avoidance of chemical processes, using solvents, etc and, especially with longer peptides, cost-effectiveness.
2o The disadvantage of making peptides by recombinant technology is that the organisms used tend to be poor at synthesising, and if necessary secreting, short sequences of amino acids. Therefore, many of the methods considered for industrial use take advantage of fusion proteins where the short peptide sequence is made as either an amino- or a carboxy-terminal extension on another protein.
Although these fusion p:oteins can be produced in greater quantities, and often purified by exploiting special characteristics of the fusion partner to simplify purification, difficulties can be experienced in recovering the peptide.
Proteins are chemically stable molecules and therefore require specific cleavage strategies in order to recover integral peptides with defined amino- and carboxy termini.
A wide panel of protein cleavage technologies can be envisaged. These range from chemical cleavage at specific amino acids to enzymatic cleavage using sequence-specific enzymes. Examples of chemical cleavage include cyanogen bromide cleavage after methionine residues and hydroxytamine cleavage between the amino acid pair asparagine - gtycine. Examples of enzymes suitable for cutting at specific protein sequences include enterokinase, which cuts after the sequence (aspartic acid)4 -lysine, and thrombin, which cuts after the basic amino acids lysine or arginine.
A common problem with both of these cleavage strategies is that sequence constraints operate on both the presence of internal sites within the peptide and the necessity to generate authentic amino-termini. For example, cyanogen bromide is ~ 5 only useful when there are no internal methionines in the peptide and thrombin can cut at a number of different sites after basic amino acids. Enzymatic cleavage has additional problems in terms of process economics. The enzyme must come from an acceptable and validated source (a common source of enterolcinase is calf gut endothelium) and be available in economically acceptable quantity.
Carboxy-terminal amidation is a common post-translational modification found on many biologically active peptides of potential commercial interest. Examples include calcitonin, magainin and etc. . In many instances, for example, calcitonin, the natural amidated peptide is nearly two thousand times as active as the non-amidated version.
There are many different chemical and biological methods designed to produce carboxy-terminal amidated peptides. However, as with any extra process step, each has disadvantages in terms of adding to the overall cost of the finished product.
This invention describes a method for the production of peptides as amino-terminal extensions of fusion proteins in recombinant systems. We provide novel methods whereby cleavage of the peptide from the fusion protein and modifications of the peptide such as carboxy-amidation can occur as a series of linked reactions in a single process. Such an approach benefits from the low cost and fidelity of synthesis in a biological expression system without the disadvantages posed by the necessity of a separate cleavage step.
Thus, in a first aspect, the present invention provides a method for the production of a peptide which comprises the step of expressing the peptide as part of a fusion protein followed ~y release of the peptide from the fusion protein by an acyl-acceptor such as a sulphur containing reductant. Suitably, at least part of the fusion ~ 5 protein is a molecule capable of catalysing transfer of the peptide, as an acyl moiety, to a suitable acceptor such as a proximal sulphur atom to form the thio-ester.
In preferred embodiments the peptide is chemically modified, eg amidated at its 2o carboxy terminus after release from the fusion protein. Suitably, the amidation step is carried out in the presence of a source of ammonium ions at a suitable pH
and the amidation step occurs simultaneously with release of the peptide. Examples of amidated peptides which could be prepared using these methods include Salmon Calcitonin, Human Calcitonin, Lutenising hormone releasing hormone, Oxytocin, 25 Gastrin neuropeptide Y, Vasopressin, Corticotrophin releasing hormone, Growth hormone releasing hormone, Human Calcitonin gene related peptide, Gastrin, D-tyr-trp-gly, phe-gly-phe-gly, gly-phe-gly, Melanocyte stimulation hormone precursor, Sectetin, Thyrotrophin releasing hormone, Amylin, Substance P, Pancreatic polypeptide, Cholecystokinin, Gastrin secretion factor, phe-his-ile, phe-tyr-tyr, Savagin, Mastoparin M, Caerulein and FMRF amide.
However, it is also possible to perform simple hydrolysis of the peptide in the absence of ammonia which would result in the formation of a free carboxylic acid terminal group. This makes the methods of the present invention suitable for the commercial production of peptides with free carboxy-termini for medicinal or other applications. Examples of such peptides include Hirulog, Magainin, thymosin alpha-1, brain naturetic peptide, attial naturetic peptide or bactericidal/permeability-increasing protein.
The methods of the present invention can for example utilise a commercially available expression vector designed for making proteins as fusion proteins.
This vector incorporates a modified self splicing protein, an intein, making it possible to liberate the protein from its fusion partner by a simple chemical reaction.
The invention utilises modified chemical conditions/steps to result in cleavage of the fusion protein thereby liberating a desired peptide, which can be modified e.g. by ambition at the carboxy-terminus.
2o Inteins are proteins which are expressed with flanking protein sequences at both amino- and carboy-termini. The amino- and carboxy-terminal sequences have been named exteins in keeping with the DNA nomenclature of exons and introns. A
seemingly typical member of the emerging family of inteins is the VMAI gene product from yeast. This is approximately SOkDa in molecular mass and contains essential amino acids at the amino terminal (Cysteine) and at the carboxy-terminal (histamine and asparagine). In addition, the carboxy-terminal extein must start with a cysteine. At some point after translation is completed, the amino-terminal peptide bond is broken and the extein transferred to the sulphur atom of the adjacent cysteine to form a thio-ester. This bond is then exchanged with the cysteine at the start of the carboxy-terminal extein and then, with participation of the adjacent asparagine, exchanged with the peptide bond at this end of the intein. The overall effect of these concerted reactions is that the two exteins are seamlessly joined and 5 the intein is released.
A detailed understanding of these reactions has emerged following the analysis of a series of mutants where essential groups at either end of the intein and the proximal ends of the exteins have been systematically replaced. This knowledge has enabled the design of mutant inteins where the amino-terminal extein can be replaced by any other protein and the self splicing function has been disabled. However, cleavage of the resulting fusion protein is still possible by the addition of extraneous chemical agents such as the reductant dithiothreitol. The fusion protein is liberated as a thio-ester with the added reductant which gradually hydrolyses to ~ 5 the free acid in solution.
Calcitonin is an example of a medically and commercially important peptide suitable for manufacture using the methods described in this invention. It contains thirty-two amino acids and is amidated at the carboxy-terminus. The functional 2o activity and amino acid sequence is highly conserved between species. Thus salmon Calcitonin , which was originally obtained mostly from natural sources but is now made by direct synthesis, is in widespread clinical use. In the past, therapies have focused on Paget's disease and hypocalcaemic shock. However, recently there has been a demand for larger amounts of material to treat osteoporosis in 25 post-menopausal women. This application requires substantive quantities of material which makes the cost of production an increasingly important factor.
In order to make Calcitonin using the intein vector it is necessary to prepare complimentary oligonucleotides which encode the Calcitonin sequence flanked by restriction sites designed for insertion at the appropriate site 5' to the modified intein. These sites must be chosen so that the coding sequence of the peptide is in the same coding frame as the rest of the expressed protein. Suitable oligonucleotides can be made by any number of methods, known to those skilled in the art, including most obviously direct synthesis and polymerise chain reaction amplification from a natural sequence using primers designed to contain convenient restriction sites. This DNA construct is then transformed into a suitable expression system and the resulting fusion protein harvested.
In a further refinement of the system the fusion protein also comprises a label, which allows for identification and/or purification of the fusion protein, and thus the peptide, by affinity or other chromatographic methods. Examples of a suitable label include a specific chitin-binding domain, or part thereof, a repeat of acidic or ~ 5 basic amino acids, a poly-histidine sequence, glutathione S transferase and lysozyme. For example, the carboxy-terminus of an intein can be fused with a specific chitin-binding domain. This binds tightly to a packed column of chitin beads and can be used for the affinity-purification of the intact fusion protein. After extensive washing, the column can then be treated with an appropriate cleavage 2o reagent and the liberated target peptide eluted.
Any expression system which can operate on a commercial scale is suitable although the intein based vector described above is designed for use in E.
coli.
Other vectors can be designed for optimal use in a particular expression system.
25 For example, if a maic~malian expression system was chosen, then protein-encoding regions should have optimised colon usage for that particular system.
Expression could also be improved by use of a smaller affinity tag for identification and/or purification such as a repeat of acidic or basic amino acids as described above, to permit resolution from contaminating proteins by ion-exchange chromatography or by the inclusion of a poly-histidine sequence for purification on a metal chelate matrix. A further modification which could improve secretion from a mammalian system (the current E. coli vector is designed for intracellular protein production) would be to add a secretory leader sequence to the calcitonin to promote secretion into the media or into the milk of transgenic animals. Suitably, such a leader sequence should be removed during the secretory process by natural processing enzymes.
1 o Examples of expression systems which could be used to express peptide fusion proteins include bacteria (E.coli, B.subtilis etc.), yeast (S. cerevisiae, P.pastoralis etc.), insect cells (S. frugiperda), mamcnaiian expression systems (chinese hamster ovary, baby hamster kidney etc.), transgenic mammalian expression in milk or other body fluids (preferably pig, cow, sheep, goat, rabbit etc) and plants (potato, ~5 corn, etc). In the case of an E.coli expression system, the initiator methionine will be retained in the expression product. Thus, where the peptide of interest is one which does not include an additional methionine in its sequence, this initiator methionine can be removed using cyanogen bromide. One example of such a peptide is Calcitonin.
Expression could be optimised for any of these systems, and for intracellular or extracellular production, by the appropriate selection of leader sequence, codon usage, intein or mutant thereof, and purification strategy. The skilled person will appreciate that this invention is not tied to any particular manifestation of intein or any species as a source. For instance, it may not be necessary to use a whole intein molecule, much of the sequence may be irrelevant to the desired process and perhaps most of the molecule is functionally unnecessary. Indeed, other proteins outside the definition of "intein" may be capable of transferring the peptide bond at WO 98!50563 PCT/GB98/01281 the carboxy-terminus of the target peptide to an appropriate thiol group thus creating the thin-ester group which is necessary for cleavage with concomitant amidation.
Thio-esters are relatively reactive chemical groups, compared to either peptide bonds or oxygen-esters, and are therefore readily converted to amides under mild reactive conditions. There are two points in the nornial cleavage and release pathway during which the fused peptide can be converted to a carboxy-terminal amide. The first and probably most suitable point is after the peptide has been released from the fusion partner by the addition of a thiol reagent. The preferred reagent is dithiothreitol but any number of sulphur-containing reductants could also function effectively. This reaction is essentially a thiol-interchange reaction where the thiol-ester formed between the carboxy-terminus of the peptide and the sulphur of the intein cysteine is transferred to one of the dithiothreitol sulphur atoms. As with any chemical reaction, the acyl shift reaction, between the amine of the cysteine at the amino-terminus of the intein and the sulphur of the same amino acid residue, is an equilibrium. With the yeast intein described above this equilibrium is shifted in favour of the amine group and the thio-ester is a minor component.
The added thiol reagent removes this thio-ester species and therefore drives the reaction in the direction of making more thio-ester until effectively all of the peptide is released as free thio-ester. The released thio-ester is relatively stable to hydrolysis by water (which would generate the unwanted free acid) and is thus suitable for cleavage by any chemical conditions which will promote amide formation.
The second point where the peptide exhibits a thio-ester is to the intein itself but as described above, this species is a minor component. However, even here it would WO 98!50563 PCT/GB98/01281 be possible to design chemical conditions to allow simultaneous release of the peptide as an amidated species.
The conditions expected to favour thin-ester cleavage with concomitant amidation are many and the following is only meant to illustrate a representitive selection of the possible reagents and reactions. Chemically, amides can be formed by the cleavage of thio-esters with ammonia and related compounds. This requires conditions where the positive charge of the carbonyl is enhanced (which is an effect of the adjacent sulphur atom) and the lone pair of electrons on the nitrogen of ammonia are available. In aqueous solution the positively-charged ammonium ion, provided by a salt such as ammonium phosphate or sulphate, is in equilibrium with uncharged ammonia, the reactive species, and the concentration of free ammonia is thus increased with a lowering of the hydrogen ion concentration. It is therefore expected that the reaction promoting the formation of the amide product, although ~ 5 likely to proceed at relatively low pH values, for example pH 4.0 to 6.0, will occur more rapidly as the pH is increased in the range 6.0 to 9.0 or even 10.0, where the equilibrium is shifted significantly in favour of ammonia formation.
The optimal range will be a compromise between the highest pH which will be 20 tolerated by the peptide substrate itself and the lowest pH whereby the reaction still proceeds at an acceptable rate. This optimum range will be determined by the sequence of the peptide itself and other factors relating to the properties of the fusion partner and to process-related, especially purification, issues.
Similar conditions and constraints are likely to apply whether the cleavage/amidation 25 reactions occur simultaneously or sequentially. There are many other chemical conditions which can be envisaged by those skilled in the art, both in aqueous and non-aqueous systems, which could achieve the desired reactions. The above is meant simply as an illustration of a suitable method and is not intended to exclude these other possible approaches.
The invention will now be described by way of the following examples, which should not be construed as limiting the invention in any way.
Example 1 : Glycine Extended Salmon Calcitonin 1.I. Cloning Strategy Vector pCYBl, obtainable from New England Biolabs, containing a NdeI site for 1 o translation initiation and a SapI site directly adjacent to the intein, was used to clone and express glycine extended salinon calcitonin (sCT-G). The sCT-G
coding sequence was synthesised as two complementary single stranded oligonucleotides of 103bases and 104bases. The codon usage was optimised for expression in E.coli. Annealing of the two strands produced 5' overhangs complementary to the Ndel (5' end) and the SapI site (3' end). The double stranded oligonucleotide was inserted into pCYB 1 digested with Ndel and Sapl.
The expression of the fusion gene is under the control of the P"~ promoter and is regulated by IPTG due to the presence of a laclq gene on the vector.
1.2. Fusion Protein Expression and Analysis The pCYB 1 vector containing sCT-G was transfected into DHS-a, cells grown, induced with IPTG, harvested and lysed by sonication. Expressed fusion was captured on chitin agarose which was washed and then boiled in SDS-PAGE
sample buffer. The supernatant was run on 16 ~ SDS-PAGE gels and the protein visualised with cooma~sie stain or electroblotted to PVDF membrane for N-terminal sequencing. The sequence analysis indicated that the sCT-G was N-terminally truncated at two positions; Ser2 and Thr6.
1.3. Fusion Protein Cleavage and Peptide Amidation Chitin agarose bound fusion was washed with 20mM Hepes pH 8.0, 40mM DTT
(cleavage buffer A) or with cleavage buffer A supplemented with 3.OM
ammonium bicarbonate (cleavage buffer B) and incubated at 4°C
overnight.
Released sCT-G was washed from the column and captured on a cation exchange resin then eluted .with a salt step. C 18 RP-HPLC analysis after digestion with trypsin showed that the product formed with cleavage buffer B contained greater than 90 % amidated C-terminus while the product with cleavage buffer A had a mixture of carboxylic C-terminus and an adduct extended by a single Cys residue, presumably from the intein N-terminus (Figure 1).
Example 2 : Leutenizing Hormone Releasing Hormone (LHRH) 2.1 Cloning Strategy Cloning was preformed exactly as described for sCT-G except that the oligonucleotides contained the LHRH coding sequence (Tan, L. and Rousseau, P.
Biochem. Biophys. Res. Com. 109: 1061-1071 (1982)).
2.2. Fusion Protein Expression and Analysis As described for sCT-G. N-terminal sequencing demonstratred the LHRH was extended at the N-terminus by a single Met residue, retained from the E.coli initiation signal.
2.3. Feision Protein Cleavage and Peptide Amidation The LHRH fusion was treated in the same manner as the sCT-G fusion until the final cation capture step. The column wash was applied directly to an elecrospray mass spectrometer and the data reconstructed to give the mass of the parent ion (Figure 2). LHRH from cleavage buffer B (as described in example 1) resulted in a parent ion with a mass of 1331Da consitent with the Met extended, amidated molecule. LHRH from cleavage buffer A (as described in example 1) gave a parent ion mass of 1332 Da consistent with the Met extended free acid. The difference of 1Da is the expected mass difference between an amide and carboxylic acid.
1 o Cloning of Human Amylin The IMPACT I (Intein Mediated Purification with an Affinity Chitin-binding Tag) protein purification system from New England Biolabs (NEB) offers 4 E. coli expression vectors, which differ in their available cloning sites. Human Amylin ~ 5 is cloned using the NEB vector pCYB 1, which contains a NdeI site for translation initiation and a SapI site directly adjacent to the intein.
The Human Amylin sequence is synthesised as two complementary single stranded oligo nucleotides of 115 and 116 bases respectively. The codon usage is 20 optimised for expression in E. toll. Annealing of the two strands produces 5' overhangs complementary to the NdeI (5' end) and the SapI site (3' end). The double stranded oligo nucleotide can be inserted directly into pCYB 1 which has previously been digested with both NdeI and SapI.
PCYB1:
5' CAT ATG GCT ACC...........................GGC TCT TCC TGC TTT 3' 3' GTA TAC CGA TCG...........................CCG AGA AGG AGC AAA 5' NdeI SapI
Human Amylin:
NdeI BspMI
CATATGAAATGCAACACCGCGACCTGCGCGACCCAGCGCCTGGCG
GTATACTTTACGTTGTGGCGCTGGACGCGCTGGGTCGCGGACCGC
MboI DdeI
AACTTCCTGGTGCATAGCAGCAACAACTTCGGCGCGATCCTGAGC
TTGAAGGACCACGTATCGTCGTTGTTGAAGCCGCGCTAGGACTCG
AGCACCAACTGGGCAGCAACACCTATTGCTTT
TCGTGGTTGACCCGTCGTTGTGGATAACGAAA
General Protcol for expressing peptide fusion proteins in E. coli and purification of fusion protein and released peptide Expression in bacteria requires transformation of cells with an expression construct using any one of a range of standard methods (Maniatis et al, supra).
After cell growth, it is usual to induce expression of the target fusion protein using a combination of an inducible promoter, for example the ~3-galactosidase promoter, and a small molecule inducer such as IPTG. The fusion protein is then recovered after cell harvesting and breakage and then purified by affinity chromatography. Most usually, this involves passing the clarified cell lysate through a column of an appropriate affinity matrix displaying a ligand to which the fusion protein binds. Contaminants are then washed from the matrix before either specific elution of the fusion protein or cleavage of the bound fusion protein in situ. For instance, with the Impact vector described in Examples 2 and 3, the fusion protein containing lysozyme would be purified by cation exchange chromatography. In this case, cleavage in situ is probably not an option, unless cleavage conditions can be found which do not promote elution of the fusion protein. Under these circumstances, cleavage in solution phase would be required. Cleavage of the fusion protein whilst bound to a matrix simplifies the subsequent purification of the peptide.
Cleavage of the fusion protein can be done by the direct addition of a thiol acyl-acceptor, such as IOmM DTT, to yield a thioester intermediate, which can subsequently be converted to the amide by treatment with ammonia salts at a pH
above 6Ø Simultaneous cleavage and conversion t an amide may also be possible with the addition of a suitable mixture of acceptor thiol and ammonia salt.
2o Released peptide is then further purified, if necessary, using conventional techniques such as solvent partitioning and HPLC.
PROTEIN
The present invention is directed to the production of peptides, especially but not exclusively with carboxy-terminal modifications such as amidation, by recombinant means.
"Peptide" is a term loosely applied to a chain of amino acids, arbitrarily applied to sequences of three to over one hundred components, but possibly more, joined via their amino- and carboxy termini. There are many examples of naturally occurring peptides which function as hormones, messengers, growth factors, antimicrobials, o surfactants etc and a wide variety of medicinal and other applications can be envisaged.
Currently, there are at least three major sources of peptides, extraction from natural sources, chemical synthesis and from organisms transformed with recombinant DNA constructs. The advantage of the route using transformed organisms is the biological fidelity of the synthetic process, the ability to synthesise chemically unfavourable sequences, the avoidance of chemical processes, using solvents, etc and, especially with longer peptides, cost-effectiveness.
2o The disadvantage of making peptides by recombinant technology is that the organisms used tend to be poor at synthesising, and if necessary secreting, short sequences of amino acids. Therefore, many of the methods considered for industrial use take advantage of fusion proteins where the short peptide sequence is made as either an amino- or a carboxy-terminal extension on another protein.
Although these fusion p:oteins can be produced in greater quantities, and often purified by exploiting special characteristics of the fusion partner to simplify purification, difficulties can be experienced in recovering the peptide.
Proteins are chemically stable molecules and therefore require specific cleavage strategies in order to recover integral peptides with defined amino- and carboxy termini.
A wide panel of protein cleavage technologies can be envisaged. These range from chemical cleavage at specific amino acids to enzymatic cleavage using sequence-specific enzymes. Examples of chemical cleavage include cyanogen bromide cleavage after methionine residues and hydroxytamine cleavage between the amino acid pair asparagine - gtycine. Examples of enzymes suitable for cutting at specific protein sequences include enterokinase, which cuts after the sequence (aspartic acid)4 -lysine, and thrombin, which cuts after the basic amino acids lysine or arginine.
A common problem with both of these cleavage strategies is that sequence constraints operate on both the presence of internal sites within the peptide and the necessity to generate authentic amino-termini. For example, cyanogen bromide is ~ 5 only useful when there are no internal methionines in the peptide and thrombin can cut at a number of different sites after basic amino acids. Enzymatic cleavage has additional problems in terms of process economics. The enzyme must come from an acceptable and validated source (a common source of enterolcinase is calf gut endothelium) and be available in economically acceptable quantity.
Carboxy-terminal amidation is a common post-translational modification found on many biologically active peptides of potential commercial interest. Examples include calcitonin, magainin and etc. . In many instances, for example, calcitonin, the natural amidated peptide is nearly two thousand times as active as the non-amidated version.
There are many different chemical and biological methods designed to produce carboxy-terminal amidated peptides. However, as with any extra process step, each has disadvantages in terms of adding to the overall cost of the finished product.
This invention describes a method for the production of peptides as amino-terminal extensions of fusion proteins in recombinant systems. We provide novel methods whereby cleavage of the peptide from the fusion protein and modifications of the peptide such as carboxy-amidation can occur as a series of linked reactions in a single process. Such an approach benefits from the low cost and fidelity of synthesis in a biological expression system without the disadvantages posed by the necessity of a separate cleavage step.
Thus, in a first aspect, the present invention provides a method for the production of a peptide which comprises the step of expressing the peptide as part of a fusion protein followed ~y release of the peptide from the fusion protein by an acyl-acceptor such as a sulphur containing reductant. Suitably, at least part of the fusion ~ 5 protein is a molecule capable of catalysing transfer of the peptide, as an acyl moiety, to a suitable acceptor such as a proximal sulphur atom to form the thio-ester.
In preferred embodiments the peptide is chemically modified, eg amidated at its 2o carboxy terminus after release from the fusion protein. Suitably, the amidation step is carried out in the presence of a source of ammonium ions at a suitable pH
and the amidation step occurs simultaneously with release of the peptide. Examples of amidated peptides which could be prepared using these methods include Salmon Calcitonin, Human Calcitonin, Lutenising hormone releasing hormone, Oxytocin, 25 Gastrin neuropeptide Y, Vasopressin, Corticotrophin releasing hormone, Growth hormone releasing hormone, Human Calcitonin gene related peptide, Gastrin, D-tyr-trp-gly, phe-gly-phe-gly, gly-phe-gly, Melanocyte stimulation hormone precursor, Sectetin, Thyrotrophin releasing hormone, Amylin, Substance P, Pancreatic polypeptide, Cholecystokinin, Gastrin secretion factor, phe-his-ile, phe-tyr-tyr, Savagin, Mastoparin M, Caerulein and FMRF amide.
However, it is also possible to perform simple hydrolysis of the peptide in the absence of ammonia which would result in the formation of a free carboxylic acid terminal group. This makes the methods of the present invention suitable for the commercial production of peptides with free carboxy-termini for medicinal or other applications. Examples of such peptides include Hirulog, Magainin, thymosin alpha-1, brain naturetic peptide, attial naturetic peptide or bactericidal/permeability-increasing protein.
The methods of the present invention can for example utilise a commercially available expression vector designed for making proteins as fusion proteins.
This vector incorporates a modified self splicing protein, an intein, making it possible to liberate the protein from its fusion partner by a simple chemical reaction.
The invention utilises modified chemical conditions/steps to result in cleavage of the fusion protein thereby liberating a desired peptide, which can be modified e.g. by ambition at the carboxy-terminus.
2o Inteins are proteins which are expressed with flanking protein sequences at both amino- and carboy-termini. The amino- and carboxy-terminal sequences have been named exteins in keeping with the DNA nomenclature of exons and introns. A
seemingly typical member of the emerging family of inteins is the VMAI gene product from yeast. This is approximately SOkDa in molecular mass and contains essential amino acids at the amino terminal (Cysteine) and at the carboxy-terminal (histamine and asparagine). In addition, the carboxy-terminal extein must start with a cysteine. At some point after translation is completed, the amino-terminal peptide bond is broken and the extein transferred to the sulphur atom of the adjacent cysteine to form a thio-ester. This bond is then exchanged with the cysteine at the start of the carboxy-terminal extein and then, with participation of the adjacent asparagine, exchanged with the peptide bond at this end of the intein. The overall effect of these concerted reactions is that the two exteins are seamlessly joined and 5 the intein is released.
A detailed understanding of these reactions has emerged following the analysis of a series of mutants where essential groups at either end of the intein and the proximal ends of the exteins have been systematically replaced. This knowledge has enabled the design of mutant inteins where the amino-terminal extein can be replaced by any other protein and the self splicing function has been disabled. However, cleavage of the resulting fusion protein is still possible by the addition of extraneous chemical agents such as the reductant dithiothreitol. The fusion protein is liberated as a thio-ester with the added reductant which gradually hydrolyses to ~ 5 the free acid in solution.
Calcitonin is an example of a medically and commercially important peptide suitable for manufacture using the methods described in this invention. It contains thirty-two amino acids and is amidated at the carboxy-terminus. The functional 2o activity and amino acid sequence is highly conserved between species. Thus salmon Calcitonin , which was originally obtained mostly from natural sources but is now made by direct synthesis, is in widespread clinical use. In the past, therapies have focused on Paget's disease and hypocalcaemic shock. However, recently there has been a demand for larger amounts of material to treat osteoporosis in 25 post-menopausal women. This application requires substantive quantities of material which makes the cost of production an increasingly important factor.
In order to make Calcitonin using the intein vector it is necessary to prepare complimentary oligonucleotides which encode the Calcitonin sequence flanked by restriction sites designed for insertion at the appropriate site 5' to the modified intein. These sites must be chosen so that the coding sequence of the peptide is in the same coding frame as the rest of the expressed protein. Suitable oligonucleotides can be made by any number of methods, known to those skilled in the art, including most obviously direct synthesis and polymerise chain reaction amplification from a natural sequence using primers designed to contain convenient restriction sites. This DNA construct is then transformed into a suitable expression system and the resulting fusion protein harvested.
In a further refinement of the system the fusion protein also comprises a label, which allows for identification and/or purification of the fusion protein, and thus the peptide, by affinity or other chromatographic methods. Examples of a suitable label include a specific chitin-binding domain, or part thereof, a repeat of acidic or ~ 5 basic amino acids, a poly-histidine sequence, glutathione S transferase and lysozyme. For example, the carboxy-terminus of an intein can be fused with a specific chitin-binding domain. This binds tightly to a packed column of chitin beads and can be used for the affinity-purification of the intact fusion protein. After extensive washing, the column can then be treated with an appropriate cleavage 2o reagent and the liberated target peptide eluted.
Any expression system which can operate on a commercial scale is suitable although the intein based vector described above is designed for use in E.
coli.
Other vectors can be designed for optimal use in a particular expression system.
25 For example, if a maic~malian expression system was chosen, then protein-encoding regions should have optimised colon usage for that particular system.
Expression could also be improved by use of a smaller affinity tag for identification and/or purification such as a repeat of acidic or basic amino acids as described above, to permit resolution from contaminating proteins by ion-exchange chromatography or by the inclusion of a poly-histidine sequence for purification on a metal chelate matrix. A further modification which could improve secretion from a mammalian system (the current E. coli vector is designed for intracellular protein production) would be to add a secretory leader sequence to the calcitonin to promote secretion into the media or into the milk of transgenic animals. Suitably, such a leader sequence should be removed during the secretory process by natural processing enzymes.
1 o Examples of expression systems which could be used to express peptide fusion proteins include bacteria (E.coli, B.subtilis etc.), yeast (S. cerevisiae, P.pastoralis etc.), insect cells (S. frugiperda), mamcnaiian expression systems (chinese hamster ovary, baby hamster kidney etc.), transgenic mammalian expression in milk or other body fluids (preferably pig, cow, sheep, goat, rabbit etc) and plants (potato, ~5 corn, etc). In the case of an E.coli expression system, the initiator methionine will be retained in the expression product. Thus, where the peptide of interest is one which does not include an additional methionine in its sequence, this initiator methionine can be removed using cyanogen bromide. One example of such a peptide is Calcitonin.
Expression could be optimised for any of these systems, and for intracellular or extracellular production, by the appropriate selection of leader sequence, codon usage, intein or mutant thereof, and purification strategy. The skilled person will appreciate that this invention is not tied to any particular manifestation of intein or any species as a source. For instance, it may not be necessary to use a whole intein molecule, much of the sequence may be irrelevant to the desired process and perhaps most of the molecule is functionally unnecessary. Indeed, other proteins outside the definition of "intein" may be capable of transferring the peptide bond at WO 98!50563 PCT/GB98/01281 the carboxy-terminus of the target peptide to an appropriate thiol group thus creating the thin-ester group which is necessary for cleavage with concomitant amidation.
Thio-esters are relatively reactive chemical groups, compared to either peptide bonds or oxygen-esters, and are therefore readily converted to amides under mild reactive conditions. There are two points in the nornial cleavage and release pathway during which the fused peptide can be converted to a carboxy-terminal amide. The first and probably most suitable point is after the peptide has been released from the fusion partner by the addition of a thiol reagent. The preferred reagent is dithiothreitol but any number of sulphur-containing reductants could also function effectively. This reaction is essentially a thiol-interchange reaction where the thiol-ester formed between the carboxy-terminus of the peptide and the sulphur of the intein cysteine is transferred to one of the dithiothreitol sulphur atoms. As with any chemical reaction, the acyl shift reaction, between the amine of the cysteine at the amino-terminus of the intein and the sulphur of the same amino acid residue, is an equilibrium. With the yeast intein described above this equilibrium is shifted in favour of the amine group and the thio-ester is a minor component.
The added thiol reagent removes this thio-ester species and therefore drives the reaction in the direction of making more thio-ester until effectively all of the peptide is released as free thio-ester. The released thio-ester is relatively stable to hydrolysis by water (which would generate the unwanted free acid) and is thus suitable for cleavage by any chemical conditions which will promote amide formation.
The second point where the peptide exhibits a thio-ester is to the intein itself but as described above, this species is a minor component. However, even here it would WO 98!50563 PCT/GB98/01281 be possible to design chemical conditions to allow simultaneous release of the peptide as an amidated species.
The conditions expected to favour thin-ester cleavage with concomitant amidation are many and the following is only meant to illustrate a representitive selection of the possible reagents and reactions. Chemically, amides can be formed by the cleavage of thio-esters with ammonia and related compounds. This requires conditions where the positive charge of the carbonyl is enhanced (which is an effect of the adjacent sulphur atom) and the lone pair of electrons on the nitrogen of ammonia are available. In aqueous solution the positively-charged ammonium ion, provided by a salt such as ammonium phosphate or sulphate, is in equilibrium with uncharged ammonia, the reactive species, and the concentration of free ammonia is thus increased with a lowering of the hydrogen ion concentration. It is therefore expected that the reaction promoting the formation of the amide product, although ~ 5 likely to proceed at relatively low pH values, for example pH 4.0 to 6.0, will occur more rapidly as the pH is increased in the range 6.0 to 9.0 or even 10.0, where the equilibrium is shifted significantly in favour of ammonia formation.
The optimal range will be a compromise between the highest pH which will be 20 tolerated by the peptide substrate itself and the lowest pH whereby the reaction still proceeds at an acceptable rate. This optimum range will be determined by the sequence of the peptide itself and other factors relating to the properties of the fusion partner and to process-related, especially purification, issues.
Similar conditions and constraints are likely to apply whether the cleavage/amidation 25 reactions occur simultaneously or sequentially. There are many other chemical conditions which can be envisaged by those skilled in the art, both in aqueous and non-aqueous systems, which could achieve the desired reactions. The above is meant simply as an illustration of a suitable method and is not intended to exclude these other possible approaches.
The invention will now be described by way of the following examples, which should not be construed as limiting the invention in any way.
Example 1 : Glycine Extended Salmon Calcitonin 1.I. Cloning Strategy Vector pCYBl, obtainable from New England Biolabs, containing a NdeI site for 1 o translation initiation and a SapI site directly adjacent to the intein, was used to clone and express glycine extended salinon calcitonin (sCT-G). The sCT-G
coding sequence was synthesised as two complementary single stranded oligonucleotides of 103bases and 104bases. The codon usage was optimised for expression in E.coli. Annealing of the two strands produced 5' overhangs complementary to the Ndel (5' end) and the SapI site (3' end). The double stranded oligonucleotide was inserted into pCYB 1 digested with Ndel and Sapl.
The expression of the fusion gene is under the control of the P"~ promoter and is regulated by IPTG due to the presence of a laclq gene on the vector.
1.2. Fusion Protein Expression and Analysis The pCYB 1 vector containing sCT-G was transfected into DHS-a, cells grown, induced with IPTG, harvested and lysed by sonication. Expressed fusion was captured on chitin agarose which was washed and then boiled in SDS-PAGE
sample buffer. The supernatant was run on 16 ~ SDS-PAGE gels and the protein visualised with cooma~sie stain or electroblotted to PVDF membrane for N-terminal sequencing. The sequence analysis indicated that the sCT-G was N-terminally truncated at two positions; Ser2 and Thr6.
1.3. Fusion Protein Cleavage and Peptide Amidation Chitin agarose bound fusion was washed with 20mM Hepes pH 8.0, 40mM DTT
(cleavage buffer A) or with cleavage buffer A supplemented with 3.OM
ammonium bicarbonate (cleavage buffer B) and incubated at 4°C
overnight.
Released sCT-G was washed from the column and captured on a cation exchange resin then eluted .with a salt step. C 18 RP-HPLC analysis after digestion with trypsin showed that the product formed with cleavage buffer B contained greater than 90 % amidated C-terminus while the product with cleavage buffer A had a mixture of carboxylic C-terminus and an adduct extended by a single Cys residue, presumably from the intein N-terminus (Figure 1).
Example 2 : Leutenizing Hormone Releasing Hormone (LHRH) 2.1 Cloning Strategy Cloning was preformed exactly as described for sCT-G except that the oligonucleotides contained the LHRH coding sequence (Tan, L. and Rousseau, P.
Biochem. Biophys. Res. Com. 109: 1061-1071 (1982)).
2.2. Fusion Protein Expression and Analysis As described for sCT-G. N-terminal sequencing demonstratred the LHRH was extended at the N-terminus by a single Met residue, retained from the E.coli initiation signal.
2.3. Feision Protein Cleavage and Peptide Amidation The LHRH fusion was treated in the same manner as the sCT-G fusion until the final cation capture step. The column wash was applied directly to an elecrospray mass spectrometer and the data reconstructed to give the mass of the parent ion (Figure 2). LHRH from cleavage buffer B (as described in example 1) resulted in a parent ion with a mass of 1331Da consitent with the Met extended, amidated molecule. LHRH from cleavage buffer A (as described in example 1) gave a parent ion mass of 1332 Da consistent with the Met extended free acid. The difference of 1Da is the expected mass difference between an amide and carboxylic acid.
1 o Cloning of Human Amylin The IMPACT I (Intein Mediated Purification with an Affinity Chitin-binding Tag) protein purification system from New England Biolabs (NEB) offers 4 E. coli expression vectors, which differ in their available cloning sites. Human Amylin ~ 5 is cloned using the NEB vector pCYB 1, which contains a NdeI site for translation initiation and a SapI site directly adjacent to the intein.
The Human Amylin sequence is synthesised as two complementary single stranded oligo nucleotides of 115 and 116 bases respectively. The codon usage is 20 optimised for expression in E. toll. Annealing of the two strands produces 5' overhangs complementary to the NdeI (5' end) and the SapI site (3' end). The double stranded oligo nucleotide can be inserted directly into pCYB 1 which has previously been digested with both NdeI and SapI.
PCYB1:
5' CAT ATG GCT ACC...........................GGC TCT TCC TGC TTT 3' 3' GTA TAC CGA TCG...........................CCG AGA AGG AGC AAA 5' NdeI SapI
Human Amylin:
NdeI BspMI
CATATGAAATGCAACACCGCGACCTGCGCGACCCAGCGCCTGGCG
GTATACTTTACGTTGTGGCGCTGGACGCGCTGGGTCGCGGACCGC
MboI DdeI
AACTTCCTGGTGCATAGCAGCAACAACTTCGGCGCGATCCTGAGC
TTGAAGGACCACGTATCGTCGTTGTTGAAGCCGCGCTAGGACTCG
AGCACCAACTGGGCAGCAACACCTATTGCTTT
TCGTGGTTGACCCGTCGTTGTGGATAACGAAA
General Protcol for expressing peptide fusion proteins in E. coli and purification of fusion protein and released peptide Expression in bacteria requires transformation of cells with an expression construct using any one of a range of standard methods (Maniatis et al, supra).
After cell growth, it is usual to induce expression of the target fusion protein using a combination of an inducible promoter, for example the ~3-galactosidase promoter, and a small molecule inducer such as IPTG. The fusion protein is then recovered after cell harvesting and breakage and then purified by affinity chromatography. Most usually, this involves passing the clarified cell lysate through a column of an appropriate affinity matrix displaying a ligand to which the fusion protein binds. Contaminants are then washed from the matrix before either specific elution of the fusion protein or cleavage of the bound fusion protein in situ. For instance, with the Impact vector described in Examples 2 and 3, the fusion protein containing lysozyme would be purified by cation exchange chromatography. In this case, cleavage in situ is probably not an option, unless cleavage conditions can be found which do not promote elution of the fusion protein. Under these circumstances, cleavage in solution phase would be required. Cleavage of the fusion protein whilst bound to a matrix simplifies the subsequent purification of the peptide.
Cleavage of the fusion protein can be done by the direct addition of a thiol acyl-acceptor, such as IOmM DTT, to yield a thioester intermediate, which can subsequently be converted to the amide by treatment with ammonia salts at a pH
above 6Ø Simultaneous cleavage and conversion t an amide may also be possible with the addition of a suitable mixture of acceptor thiol and ammonia salt.
2o Released peptide is then further purified, if necessary, using conventional techniques such as solvent partitioning and HPLC.
Claims (31)
1. A method for the production of a peptide, which comprises the step of expressing the peptide as part of a fusion protein, followed by release of the peptide from the fusion protein by an acyl-acceptor, such as a sulphur containing reductant.
2. A method as claimed in claim 1 wherein at least part of the fusion protein is a molecule capable of catalysing transfer of the peptide, as an acyl moiety to a suitable acceptor, such as a proximal sulphur atom to form a thin-ester.
3. A method as claimed in claim 1 or claim 2 wherein the peptide is amidated at its carboxy terminus after release from the fusion protein.
4. A method as claimed in claim 3 wherein the amidation step is carried out in the presence of a source of ammonium ions at a suitable pH.
5. A method as claimed in claim 3 or claim 4 wherein the amidation step occurs simultaneously with release of the peptide
6. A method as claimed in any one of claims 1 to 5 wherein the peptide is Salmon Calcitonin, Human Calcitonin, Lutenising hormone releasing hormone, Oxytocin, Gastrin neuropeptide Y, Vasopressin, Corticotrophin releasing hormone, Growth hormone releasing hormone, Human Calcitonin gene related peptide, Gastrin, D-tyr-trp-gly, phe-gly-phe-gly, gly-phe-gly, Melanocyte stimulation hormone precursor, Sectetin, Thyrotrophin releasing hormone,, Amylin, Substance P, Pancreatic polypeptide, Cholecystokinin, Gastrin secretion factor, phe-his-ile, phe-tyr-tyr, Savagin, Mastoparin M, Caerulein or FMRF amide.
7. A method as claimed in claim 6 wherein the peptide is Salmon Calcitonin or Human calcitonin.
8. A method as claimed in any one of claims 2 to 7 wherein the fusion protein comprises at least part of a modified intein sequence.
9. A method as claimed in claim 8 wherein the modification of the intein sequence, or part thereof, results in disablement of the self splicing function.
10. A method as claimed in claim 8 or claim 9 wherein the intein sequence, or part thereof, is derived from the VMA1 gene from yeast.
11. A method as claimed in claim 1 or claim 2 wherein the peptide is released from the fusion protein by hydrolysis.
12. A method as claimed in claim 11 wherein the peptide is Hirulog, Magainin, thymosin alpha-1, brain naturetic peptide, atrial naturetic peptide or bactericidal/permeability-increasing protein.
13. A method as claimed in any one of claims 1 to 12 wherein the fusion protein comprises a label, which allows for identification andlor purification of the fusion protein by affinity or other chromatographic methods.
14. A method as claimed in claim 13 wherein the label is an affinity label.
15. A method as claimed in claim 14 wherein the affinity label comprises a specific chitin-binding domain, or part thereof, a repeat of acidic or basic amino acids, a poly-histidine sequence, glutathione synthetase and lysozyme.
16. A method as claimed in any one of claims 1 to 15 wherein the fusion protein is expressed in bacteria, yeast, plant tissue, including whole plants, insect cells, mammalian cells or in a body fluid of a transgenic mammal.
17. A method as claimed in claim 15 wherein the fusion protein is expressed in E.coli or B.subtilis.
18. A method as claimed in claim 17 wherein the fusion protein is expressed in E. coli and wherein the peptide is treated with cyanogen bromide if it does not contain a methionine in its sequence.
19. A method as claimed in claim 15 wherein the fusion protein is expressed in S.cerevisiae or P.pastoralis.
20. A method as claimed in claim 15 wherein the fusion protein is expressed in chinese hamster ovary cells or baby hamster kidney cells.
21. A method as claimed in claim 15 wherein the fusion protein is expressed in transgenic potato tissue or transgenic corn tissue.
22. A method as claimed in claim 15 wherein the fusion protein is expressed in the mills of a transgenic pig, cow, sheep, goat or rabbit.
23. A method as claimed in claim 15 wherein the fusion protein is expressed in insect cells, e.g. in the S. frugiperda cells.
24. A method as claimed in any one of claims 1 to 23 wherein the sequence coding for the fusion protein also includes a secretory leader sequence.
25. A method as claimed in claim 24 wherein the secretory leader is removed by natural processing enzymes during secretion.
26. A DNA construct coding for a fusion protein as defined in any one of claims 1, 2, 6 to 15, 24 or 25.
27. A DNA construct as claimed in claim 26 which is in the form of a vector.
28. A host cell transformed or transfected with a DNA construct as defined in claim 26 or claim 27.
29. A host cell as claimed in claim 28 modified by any one or more of the features of claims 16 to 21.
30. A transgenic, non-human, mammal, which has incorporated in its genome a DNA construct as, defined in claim 26.
31. A transgenic mammal as claimed in claim 29 which is a transgenic pig, cow, sheep, goat or rabbit.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9708918.9A GB9708918D0 (en) | 1997-05-01 | 1997-05-01 | Methods |
GB9708918.9 | 1997-05-01 | ||
PCT/GB1998/001281 WO1998050563A1 (en) | 1997-05-01 | 1998-05-01 | Methods of production of an amidated peptide through the use of a fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2287204A1 true CA2287204A1 (en) | 1998-11-12 |
Family
ID=10811692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002287204A Abandoned CA2287204A1 (en) | 1997-05-01 | 1998-05-01 | Methods of production of an amidated peptide through the use of a fusion protein |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0979291A1 (en) |
JP (1) | JP2001525664A (en) |
KR (1) | KR20010012165A (en) |
CN (1) | CN1254379A (en) |
AU (1) | AU7224498A (en) |
CA (1) | CA2287204A1 (en) |
GB (1) | GB9708918D0 (en) |
NZ (1) | NZ500507A (en) |
WO (1) | WO1998050563A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046317A (en) * | 1997-12-19 | 2000-04-04 | Hormos Medical Oy, Ltd. | DNA molecule encoding a mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
US6312898B1 (en) | 1999-04-15 | 2001-11-06 | Hormos Medical Oy, Ltd. | Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene |
WO2001012820A1 (en) * | 1999-08-17 | 2001-02-22 | Health Research Institute | Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity |
KR20020039346A (en) * | 1999-09-17 | 2002-05-25 | 추후보정 | Subunit optimized fusion proteins |
ZA200203041B (en) | 1999-11-12 | 2003-12-09 | Oncolytics Biotech Inc | Viruses for the treatment of cellular proliferative disorders. |
ES2352204T3 (en) | 2004-10-19 | 2011-02-16 | Lonza Ag | SOLID PHASE PEPTIDIC SYNTHESIS METHOD. |
WO2006132925A2 (en) | 2005-06-01 | 2006-12-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
JP4934397B2 (en) * | 2006-10-19 | 2012-05-16 | 学校法人順天堂 | Transgenic non-human animals |
WO2010028122A1 (en) | 2008-09-03 | 2010-03-11 | Scinopharm Taiwan Ltd. | Process for making bivalirudin |
DK2382232T3 (en) | 2008-12-29 | 2013-12-16 | Lonza Braine Sa | Process for the preparation of bivalirudin |
JP2016519950A (en) | 2013-05-31 | 2016-07-11 | ノヴォ ノルディスク アー/エス | Method for producing peptides using engineered inteins |
WO2016130899A1 (en) | 2015-02-13 | 2016-08-18 | The Board Of Trustees Of The University Of Illinois | Peptide inhibition of ccr3-mediated diseases or conditions |
KR102000490B1 (en) * | 2018-01-12 | 2019-10-01 | 전남대학교산학협력단 | Transformants for expressing flagellin protein derived from Salmonella sp. with improved solubility, preparation method and use thereof |
WO2021021774A1 (en) | 2019-07-29 | 2021-02-04 | The Board Of Trustees Of The University Of Illinois | Composition and method for promoting wound healing |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9127250D0 (en) * | 1991-12-23 | 1992-02-19 | Unilever Plc | Modification |
JPH07509128A (en) * | 1992-07-13 | 1995-10-12 | バイオネブラスカ・インコーポレーテッド | Methods for modifying recombinant polypeptides |
GB9406974D0 (en) * | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
EP0835323A4 (en) * | 1995-06-28 | 1999-08-11 | New England Biolabs Inc | Modified proteins and methods of their production |
-
1997
- 1997-05-01 GB GBGB9708918.9A patent/GB9708918D0/en active Pending
-
1998
- 1998-05-01 JP JP54783598A patent/JP2001525664A/en active Pending
- 1998-05-01 CN CN98804740A patent/CN1254379A/en active Pending
- 1998-05-01 NZ NZ500507A patent/NZ500507A/en unknown
- 1998-05-01 EP EP98919369A patent/EP0979291A1/en not_active Withdrawn
- 1998-05-01 KR KR19997010114A patent/KR20010012165A/en not_active Application Discontinuation
- 1998-05-01 CA CA002287204A patent/CA2287204A1/en not_active Abandoned
- 1998-05-01 WO PCT/GB1998/001281 patent/WO1998050563A1/en not_active Application Discontinuation
- 1998-05-01 AU AU72244/98A patent/AU7224498A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001525664A (en) | 2001-12-11 |
WO1998050563A1 (en) | 1998-11-12 |
GB9708918D0 (en) | 1997-06-25 |
AU7224498A (en) | 1998-11-27 |
KR20010012165A (en) | 2001-02-15 |
NZ500507A (en) | 2001-08-31 |
CN1254379A (en) | 2000-05-24 |
EP0979291A1 (en) | 2000-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU605291B2 (en) | Process for the purification of recombinant polypeptides | |
US7105638B1 (en) | Product and process for the production, isolation, and purification of recombinant polypeptide | |
CA2287204A1 (en) | Methods of production of an amidated peptide through the use of a fusion protein | |
Basilion et al. | The iron-responsive element-binding protein: localization of the RNA-binding site to the aconitase active-site cleft. | |
US5962270A (en) | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs | |
AU601273B2 (en) | Leader sequences for the production of recombinant proteins | |
FI113272B (en) | Improved protein folding method | |
AU765206B2 (en) | Process for producing peptide with the use of accessory peptide | |
AU707631B2 (en) | Peptide production as fusion protein in transgenic mammal milk | |
ATE291627T1 (en) | CHIMERA OF G-PROTEIN | |
SAITO-NAKATSUKA et al. | Reactive Sulfhydryl Groups of Sarcoplasmic Reticulum ATPase. I. Location of a Group Which Is Most Reactive with N-Ethyhnaleimide | |
US20020146779A1 (en) | Methods for production of recombinant polypeptides | |
WO1999007735A2 (en) | Recombinant expression of insulin c-peptide | |
CA2324513A1 (en) | Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production | |
CN106755042B (en) | Preparation method of bioactive small peptide based on combined self-shearing and protein scaffold | |
HU216335B (en) | Process for producing peptides | |
Polyak et al. | Introduction of spacer peptides N-terminal to a cleavage recognition motif in recombinant fusion proteins can improve site-specific cleavage. | |
CN115851667A (en) | Method for regulating and controlling activity of recombinant nuclease | |
JP3346563B2 (en) | Improved method for purifying recombinant proteins and compounds useful in the method | |
US5416007A (en) | Enhanced proteolytic cleavage of recombinant fusion proteins | |
Morreale et al. | Bioprocess‐centered molecular design (BMD) for the efficient production of an interfacially active peptide | |
EP0578472A2 (en) | A process for recovering peptides expressed as fusion proteins | |
Kato et al. | Efficient production of Casoxin D, a bradykinin agonist peptide derived from human casein, by Bacillus brevis | |
KR100305726B1 (en) | The Method for Expressing Polypeptides in E.coli Using Carboxypeptidase Y propeptide as a Fusion partner, Recombinant Vector Used thereby and Transformant thereof | |
Oh et al. | Use of carboxypeptidase Y propeptide as a fusion partner for expression of small polypeptides in Escherichia coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |